VivoSeq
Other

Treatment Duration

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Treatment Duration is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Completed3 · 60%
Not yet recruiting1 · 20%
Unknown status1 · 20%

Clinical Trials

Trial Activity

Defining Antibiotic Treatment Duration for Ventilator - Associated Lung Infection
Completed·UUniversity of Oxford·Phase 3·NCT03382548·460 enrolled
Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents
Completed·UUniversity of Texas Southwestern Medical Center·N/A·NCT00332787·200 enrolled
Using Biomarkers to Predict TB Treatment Duration
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02821832·946 enrolled
Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)
Not yet recruiting·UUniversity College, London·Phase 3·NCT07163143·784 enrolled
Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC
Unknown status·UUniversity of Milano Bicocca·N/A·NCT05418660·300 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)